EGFR and lung adenocarcinoma: Our predictive model integrating spectral CT parameters, AI-quantified imaging biomarkers, and clinical indicators demonstrated discriminative capability for EGFR-mutant versus wild-type lung adenocarcinoma, achieving an AUC of 0.713 (95% CI: 0.628-0.797).